Literature DB >> 26361860

Prevalence of resistant hypertension and associated factors in Japanese subjects with type 2 diabetes.

H Yokoyama1, S Araki2, S Watanabe3, J Honjo4, S Okizaki5, D Yamada3, R Shudo3, H Shimizu3, H Sone6, M Haneda7.   

Abstract

OBJECTIVE: The prevalence of treatment resistant hypertension (RH) depends on methods used for blood pressure (BP) measurements, goals of BP, and therapeutic efforts in terms of medication and adherence. We focused on diabetic subjects and explored the prevalence of RH in primary care practice.
METHODS: In 1737 subjects with type 2 diabetes who continued regular visits, office BP was evaluated by multiple measurements over one year. RH was defined as using more than four antihypertensive drugs or failure to achieve the goal with three antihypertensive drugs from different classes. The RH prevalence was investigated with BP goals <130/80 and 140/90 mmHg.
RESULTS: The percentage of subjects who achieved BP goals <130/80 and 140/90 were 70.5% and 93.8% with adherence to medication ≥95%, and the corresponding prevalence rates of RH in treated subjects were 28.4% and 21.8%, respectively. Factors independently associated with RH were age (odds ratio 1.02 [95% CI 1.01-1.04]), body mass index (1.10 [1.06-1.13]), variability in systolic BP (1.06 [1.02-1.09]), triglycerides (2.86 [1.34-6.11]), macroalbuminuria (3.33 [2.03-5.48]), estimated glomerular filtration rate (0.98 [0.97-0.99]), retinopathy (1.91 [1.39-2.61]), and family history of hypertension (1.85 [1.23-2.21]). Worsening albuminuria and glomerular filtration rate enhanced the prevalence of RH in a graded manner.
CONCLUSION: Careful estimation of office BP values over one year with a high achievement of BP goals and adequate adherence revealed that the prevalence of RH in type 2 diabetes is high. RH was characterized by accumulation of cardiovascular genetic and environmental risks.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Prevalence; Resistant hypertension; Risk factors; Therapeutics; Type 2 diabetes mellitus

Mesh:

Substances:

Year:  2015        PMID: 26361860     DOI: 10.1016/j.diabres.2015.08.007

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  4 in total

Review 1.  Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2016-04       Impact factor: 5.369

2.  Individualized prevention against hypertension based on Traditional Chinese Medicine Constitution Theory: A large community-based retrospective, STROBE-compliant study among Chinese population.

Authors:  Ying Li; Xiao-Hui Li; Xin Huang; Lu Yin; Cheng-Xian Guo; Chang Liu; Yong-Mei He; Xing Liu; Hong Yuan
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.889

3.  The prevalence and predictors of resistant hypertension in high-risk overweight and obese patients: A cross-sectional study based on the 2017 ACC/AHA guidelines.

Authors:  Faris Haddadin; Karan Sud; Alba Munoz Estrella; Sananda Moctezuma; Lingling Wu; Joshua Berookhim; Claire Huang Lucas; Dipal Patel; Edgar Argulian
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-26       Impact factor: 3.738

Review 4.  Resistant hypertension-defining the scope of the problem.

Authors:  Richard Chia; Ambarish Pandey; Wanpen Vongpatanasin
Journal:  Prog Cardiovasc Dis       Date:  2019-12-19       Impact factor: 11.278

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.